Tianjin International Joint Research and Development Centre of Ophthalmology and Vision Science, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, China.
Tianjin Open University College of Social Education, Tianjin, China.
Ophthalmic Epidemiol. 2024 Jun;31(3):240-248. doi: 10.1080/09286586.2023.2232462. Epub 2023 Aug 1.
Atropine eye drops have been shown to slow the progression of myopia, but there has been limited research on the effectiveness of 0.05% atropine in treating myopia. This study aimed to investigate the safety and efficacy of 0.05% atropine eye drops in controlling myopia in children.
The study included 424 participants aged 6 to 12 years between January 1, 2015, and January 1, 2021. Of these, 213 were randomly assigned to the 0.05% atropine group and 211 to the placebo group. The cycloplegic spherical equivalent (SE), axial length (AL), corneal curvature (K), and anterior chamber depth (ACD) were measured using IOLMaster. The lens power and corneal astigmatism were also determined. The changes in ocular biometric parameters were compared between the two groups, and the contributions of ocular characteristics to SE progression were calculated and compared.
Over a 12-month period, the changes in spherical equivalent were -0.03 ± 0.28 and -0.32 ± 0.14 in the atropine and placebo groups, respectively ( = .01). The changes in axial length were 0.06 ± 0.11 and 0.17 ± 0.12, respectively ( = .01). At 18 and 24 months, there were significant differences in axial length and spherical equivalent between the atropine and placebo groups. Multiple regression models accounting for changes in AL, K, and lens magnification explained 87.23% and 98.32% of SE changes in the atropine and placebo groups, respectively. At 1 year ( = .01) and 2 years ( = .03), there were significant differences in photophobia between the atropine and placebo groups.
This two-year follow-up study demonstrates that 0.05% atropine eye drops are safe and effective in preventing the development of myopia in school-aged children.
阿托品眼药水已被证明可减缓近视的进展，但关于 0.05%阿托品治疗近视的疗效研究有限。本研究旨在探讨 0.05%阿托品眼药水控制儿童近视的安全性和有效性。
该研究纳入了 2015 年 1 月 1 日至 2021 年 1 月 1 日期间年龄为 6 至 12 岁的 424 名参与者。其中 213 名被随机分配至 0.05%阿托品组，211 名被分配至安慰剂组。使用 IOLMaster 测量睫状肌麻痹球镜等效（SE）、眼轴（AL）、角膜曲率（K）和前房深度（ACD）。还确定了晶状体屈光力和角膜散光。比较两组之间眼生物测量参数的变化，并计算和比较眼特征对 SE 进展的贡献。
在 12 个月的时间内，阿托品组的 SE 变化为-0.03±0.28，安慰剂组为-0.32±0.14（ = .01）。AL 的变化分别为 0.06±0.11 和 0.17±0.12（ = .01）。在 18 个月和 24 个月时，阿托品组和安慰剂组的 AL 和 SE 变化有显著差异。考虑到 AL、K 和晶状体放大率变化的多变量回归模型分别解释了阿托品组和安慰剂组 SE 变化的 87.23%和 98.32%。在 1 年（ = .01）和 2 年（ = .03）时，阿托品组和安慰剂组之间的畏光有显著差异。
这项为期两年的随访研究表明，0.05%阿托品眼药水可安全有效地预防学龄儿童近视的发展。
